Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]
Aptinyx reported positive results from a phase 2 trial evaluating NYX-783 versus placebo in patients with post-traumatic stress disorder (PTSD). […]
Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]
Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are […]
ACADIA Pharmaceuticals announced top-line results from its Phase 3 CLARITY study which combined two identical studies evaluating the efficacy, safety […]
BioXcel Therapeutics announced that BXCL501, a proprietary sublingual thin film of dexmedetomidine, met the primary and secondary endpoints in the […]
Biohaven Pharmaceuticals announced positive topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). […]
Axsome Therapeutics announced top-line results from the phase 3 STRIDE-1 trial evaluating AXS-05 versus active comparator bupropion for treatment of […]
Alkermes announced that the peer-reviewed publication, Journal of Clinical Psychiatry, has published data from the phase 3 ENLIGHTEN-1 clinical trial […]
The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to […]